Anti-müllerian hormone levels as indicator of female general health status: a cross-sectional study

ABSTRACT Research question To evaluate the correlation between clinical and hormonal parameters and comorbidity burden in Caucasian women presenting for fertility treatment Design Monocentric cross-sectional study including a cohort of 3163 Caucasian women seeking medical care for fertility treatment. All the patients underwent centralized laboratory testing for hormonal assessment. Complete clinical and laboratory data from the entire cohort were retrospectively analysed. Comorbidity burden score was assessed by Charlson Comorbidity Index (CCI; categorized as 0 vs. 1 vs. ≥2). Results Descriptive statistics and regression models tested the associations between clinical and laboratory parameters and CCI. Among the entire cohort of patients, a CCI = 0 was found in 2977 women (94.1%), a CCI = 1 and CCI ≥ 2 were found in 113 (3.6%) and 73 (2.3%) patients respectively. Age, gravidity, Anti-Mullerian hormone (AMH) and thyroid stimulating hormone (TSH) values were found to be significantly different among CCI groups (all p≤ 0.01). At regression models, age at presentation and AMH emerged as independent indicator of CCI≥1. Age at presentation Conclusions A younger age at presentation and lower AMH levels are significant independent indicators of decreased general health in women requiring clinical evaluation for fertility treatment. As observed for sperm parameters in men, AMH might serve as a proxy of women's general health status.